Huntington’s disease Archives - Page 2 of 2

uniQure Begins First AAV Gene Therapy Trial for Huntington’s Disease

Adeno-Associated Virus (AAV), Cells, Clinical Trials, DNA, Gene Therapy, Hereditary Diseases, Huntington’s disease, Muscles, R&D, RNA

Gene therapy pioneer uniQure launched the first-in-human adeno-associated virus-based gene therapy clinical trial for Huntington’s disease.

August 4, 2020/by BioSpace

Research Roundup: Antihistamines Might Slow Down Huntington’s and More

Abnormal Blood Vessels, Antihistamines, California, Coronavirus Disease 2019 (COVID-19), Fat, Gut Bacteria, Huntington’s disease, Molecules, Neurological Disorders, R&D, University of Chicago

A review of some recently published scientific studies includes one for antihistamines and similar compounds that might slow down Huntington’s disease.

June 12, 2020/by BioSpace

Active Biotech Pivots Away from MS and Huntington’s Disease

Business, Clinical Trials, Collaborations, Huntington’s disease, Multiple Sclerosis, Neurodegeneration, New Direction, R&D, Small Molecules, Solid Tumors

A new business direction was approved by the board of directors for Lund, Sweden-based Active Biotech.

February 5, 2020/by BioSpace

Wave Life Sciences and Takeda Form Global Strategic Collaboration to Advance Therapies for Central Nervous System Disorders

Alzheimer’s Disease, Amyotrophic Lateral Sclerosis (ALS), Biotechnology, Central Nervous System, CNS Disorders, Collaboration, Duchenne Muscular Dystrophy (DMD), Frontotemporal Dementia (FTD), Genes, Huntingtin (HTT) Gene, Huntington’s disease, Issue Archives, Parkinson’s disease, Spinocerebellar Ataxia Type 3 (SCA3)

Wave Life Sciences Ltd. announced the formation of a global strategic collaboration with Takeda Pharmaceutical Company Ltd. to discover, develop and commercialize nucleic acid therapies for disorders of the central nervous system.

February 20, 2018/by Administrator